Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 28, 2013; 19(40): 6834-6841
Published online Oct 28, 2013. doi: 10.3748/wjg.v19.i40.6834
Published online Oct 28, 2013. doi: 10.3748/wjg.v19.i40.6834
Figure 1 Study patient flow.
HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B.
Figure 2 Cumulative risk.
A, B: Hepatocellular carcinoma (HCC) in cirrhotic patients and in HBeAg (+) patients with drug-resistant chronic hepatitis B (CHB) (log rank test, P < 0.001, P = 0.008, respectively); C, D: HCC in YIDD patients and in patients > 50 years of age with drug-resistant CHB (log rank test, P =0.007, P = 0.001, respectively); E: HCC in complete virologic responders with drug-resistant CHB (log rank test, P = 0.003).
- Citation: Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B. World J Gastroenterol 2013; 19(40): 6834-6841
- URL: https://www.wjgnet.com/1007-9327/full/v19/i40/6834.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i40.6834